Canada (EN)
CLINICAL CASE
Immediate implant placement in a site with severe buccal dehiscence
Dr. Ferdinando D'Avenia
“creos™ xenogain is a user-friendly bone grafting material: hydration, manipulation and positioning is simplified by its wettability coupled with a smart syringe packaging that really makes things easy.”
Initial clinical situation
Initial situation: pre-operative CBCT images (left).
Clinical pre-surgical situation (right).
Surgical procedure
After atraumatic tooth extraction, the granulation tissue is completely removed. The osteotomy is prosthetically driven, in order to provide a second premolar screw retained restoration with an occlusal screw access hole. In order to satisfy this criteria, the implant is more favorably housed in predominantly native bone, mesio-lingually to the center of the defect (left).
The implant (NobelParallel™ CC RP 4.3 x 13 mm) is placed with 20 Ncm insertion torque, with buccal threads exposed to the defect area (without bone contact) (right).
Placement of creos™ xenoprotect inside the extraction socket to protect creos™ xenogain from exposure to the soft tissue through dehiscence (left).
Hydration of creos™ xenogain with venous blood (right).
Placement of creos™ xenogain into the bony defect. The implant is covered with a 3 mm healing abutment (Ø 3.6 mm) (left).
Healing after 8 days with slight membrane exposure (right).
Post-operative CBCT showing sufficient bone augmentation of the buccal wall dehiscence (left).
120 day follow-up: during the final impression visit, the healing abutment is changed. A wider diameter allows a better management of the final restoration emergency profile (right).
Restorative procedure
CBCT after healing.
Outcome
Final restoration.
Share this clinical case
© Nobel Biocare Services AG, 2020. All rights reserved. Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case, trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Product images are not necessarily to scale. Disclaimer: Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office for current product assortment and availability. For prescription use only. Caution: Federal (United States) law restricts this device to sale by or on the order of a licensed clinician, medical professional or physician. See Instructions For Use for full prescribing information, including indications, contraindications, warnings and precautions. Nobel Biocare does not take any liability for any injury or damage to any person or property arising from the use of this clinical case. This clinical case is not intended to recommend any measures, techniques, procedures or products, or give advice, and is not a substitute for medical training or your own clinical judgement as a healthcare professional. Viewers should never disregard professional medical advice or delay seeking medical treatment because of something they have seen in this clinical case. Full procedure is not shown. Certain sequences have been cut. Legal manufacturer of creos™ xenogain is NIBEC Co, Iwol electricity-electronic Agro-Industrial Complex, 116, Bamdi-gil, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do, 27816, Korea.